Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells

Molecular Human Reproduction

Volumn 3, Issue 12, 1997, Pages 1019-1027

  Hochner Celnikier, Drorith ^a   Greenfield, Caryn ^a   Finci Yeheskel, Zwezdana ^a   Milwidsky, Ariel ^a   Gutman, Alisa ^a   Goldman Wohl, Debra ^a   Yagel, Simcha ^a   Mayer, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Endometrium; Gelatinase; Plasminogen activation; Protein p53; Tamoxifen

Indexed keywords

ESTRADIOL; GELATINASE; GLYCOGEN; GLYCOGEN SYNTHASE; PHOSPHORYLASE; PLASMINOGEN ACTIVATOR; PROTEIN P53; TAMOXIFEN;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; ENDOMETRIUM TUMOR; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PROTEIN BINDING;

ADENOCARCINOMA; CELL DIVISION; DRUG COMBINATIONS; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; ESTRADIOL; FEMALE; GELATINASES; GLYCOGEN; GLYCOGEN SYNTHASE; HUMANS; PHOSPHORYLASES; PLASMINOGEN ACTIVATORS; PROTEIN BINDING; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031302443     PISSN: 13609947     EISSN: None     Source Type: Journal    
DOI: 10.1093/molehr/3.12.1019     Document Type: Article

References (52)

1. Ahn, Y.S., Zerban, H., Grobholtz, R. et al. (1992) Sequential changes in glycogen content, expression of glucose transporters and enzymic patterns during development of clear/acidophilic cell tumors in rat kidney. Carcinogenesis, 13, 2329-2334.
2. Anzai, Y., Holinka, C.F., Kuramoto, H. et al. (1989) Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res., 49, 2362-2365.
3. Barakat, R.R. (1996) Tamoxifen and endometrial neoplasia. Clin. Obstet. Gynecol., 39, 629-640.
4. Barash, V., Schramm, H. and Gutman, A. (1977) Regulation of glycogen synthetase and phosphorylase phosphatase activities in rat adipose tissue. Biochim. Biophys. Acta. 481, 86-95.
5. Berchuck, A., Kohler, M.F. Marks, J.R. et al. (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170, 246-252.
6. Bonfil, R.D., Farias, E and Ruggeri, B. (1995) Secretion of gelatinases by human pancreatic cancer cell lines- lack of correlation with invasive ability. Acta Physiol. Pharmacol. Ther. Latinoam , 45, 185-91.
7. Bulletti, C., Jassoni, V.M., Polli, V et al. (1991) Basement membrane in human endometrium. possible role of proteolytic enzymes in developing hyperplasia and carcinoma. Ann. N.Y. Acad. Sci., 622, 376-820.
8. Butta, A., McLennan, K., Flanders, K.C. et al. (1992) Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264.
9. Casslen, B., Urano, S., Lecander, I. et al. (1992) Plasminogen activators in the human endometrium, cellular origin and hormonal regulation. Blood Coag. Fibrinol., 3, 133-138.
10. Croxtall, J.D., Elder, M.G. and White, J.O. (1990) Hormonal control of proliferation in the Ishikawa endometrial adenocarcinoma cell line. J. Steroid Biochem., 35, 665-669.
11. Daniel, Y., Peyser, M.R., Inbar, M. et al. (1996) The effects of tamoxifen treatment on the endometrium. Fertil. Steril., 65, 1083-1089.
12. Dano, K., Andreasen, P., Grondahl-Hansen, J. et al. (1985) Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266.
13. Deutsch, D.G. and Mertz, E.T. (1970) Plasminogen: purification from human plasma by affinity chromatography. Science, 170, 1095-1096.
14. Furr, B.J.A and Jordan, V.C. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther., 25, 127-205.
15. Gleeson, N.C., Gonsales, R. and Bonnar, J. (1993) Plasminogen activator inhibitors in endometnal adenocarcinoma. Cancer, 72, 1670-1672.
16. Gravanis, A. and Gurpide, E. (1986) Effects of estradiol on deoxyribonucleic acid polymerase alpha activity in the Ishikawa human endometrial adenocarcinoma cell line. J. Clin. Endocrinol. Metab. 63, 356-359.
17. Harris, C.C. (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 262, 1980-1981.
18. Higazi, A.A.-R., Finci-Yeheskel, Z., Samara, A.A.-R. et al. (1992) Stimulation of plasmin activity by oleic acid. Biochem. J., 282, 863-866.
19. Hochner-Celnikier, D., Anteby, E., Shimonovitz, S. et al. (1996) The gynecological side effects of tamoxifen therapy for breast cancer. Proposal for follow up and treatment. Isr. J. Obstet. Gynecol., 7, 117-124.
20. Holinka, C.F., Hata, H., Gravanis, A. et al. (1986) Effects of estradiol on proliferation of endometnal adenocarcinoma cells (Ishikawa line). J. Steroid Biochem., 25, 781-786.
21. Hollstein, M., Sidransky, D., Vogelstein, B. et al. (1991) P53 mutations in human cancers. Science, 253, 49-53.
22. Hurwitz, A., Dushnik, M., Solomon, H. et al. (1993) Cytokine-mediated regulation of rat ovarian function: Interleukin-1 stimulates the accumulation of a 92-kilodalton gelatinase. Endocrinology, 132, 2709-2714.
23. Hurwitz, A., Lavy, Y., Finci-Yeheskel, Z. et al. (1995) Interleukin-1 mediated stimulation of prostaglandin E production is without effect on plasminogen activator activity in human granulosa lutein cell cultures. J. Clin. Endocrinol. Metab., 80, 3018-3024.
24. Ismail, S.M. (1996) The effects of tamoxifen on the uterus. Curr. Opin. Obstet. Gynecol., 8, 27-31.
25. Jordan, V.C. and Murphy, C.S. (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11, 578-610.
26. Kassan, S., Mechanic, J.I. and Gurpide, E. (1989) Altered estrogen receptor system in estrogen -unresponsive human endometrial adenocarcinoma cells. J. Steroid Biochem., 33, 327-333.
27. Kuramoto, H., Hamano, M., Nishida, M. et al. (1976) Establishment of a new human endometnal carcinoma cell line derived from ascites. Acta Obstet. Gynecol. Jap., 28, 1405-1406.
28. Kwaan, H.C. (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev., 11, 291-311.
29. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell., 88, 323-331.
30. Lutzker, S. and Levine, A. J. (1966) A functionally inactive p53 protein in embryonal carcinoma cells is activated by DNA damage or cellular differentiation. Nature Med., 2, 804-810.
31. Mayer, M. (1990) Biochemical and biological aspects of the plasminogen activation system. Clin. Biochem., 23, 197-211.
32. Mouvais, J., Kutten, F and Gompel, A. (1986) Estradiol/progesterone interaction in normal and pathologic breast cells. Ann. N.Y. Acad. Sci., 464, 152-67.
33. Nayfield, S.G., Karp, J.E., Ford, L.G. et al. (1991) Potential role of tamoxifen in prevention of breast cancer. J. Natl. Cancer Inst., 83, 1450-1459.
34. Nephew, P., Polek, T.C., Akcali, K.C. et al. (1993) The antiestrogen tamoxifen induces c-fos and jun-B, but not c-jun or jun-D, protooncogenes in the rat uterus. Endocrinology, 133, 419-422.
35. Nishida, M., Kasahara, K., Kaneko, M. et al. (1985) Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet. Gynecol. Jap., 37, 1103-1111.
36. Ossowski, L., Clunie, G., Masucci, M.T. et al. (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol., 115, 1107-1112.
37. Rechberger, T., Postawski, K., Skorupski, P. et al. (1996) Local activity of matrix metalloproteinases in a case of botryoid sarcoma. Eur. J. Obstet. Gynecol. Reprod. Biol., 67, 169-172.
38. Saksela, O. and Rifkin, D.B. (1988) Cell-associated plasminogen activation: regulation and physiological function. Ann. Rev. Cell Biol., 4, 93-126.
39. Sato, H., Takino, T., Okada, Y. et al. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370, 61-65.
40. Schmitt, M., Wilhelm, O., Janicke, F. et al. (1995) Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J. Obstet. Gynecol., 21, 151-165.
41. Shelepov, V.P., Chekulaev, V.A. and Pasha-Zade, G.R. (1991) Factors within the body determining the glycogen reserves in the tissues of rats with transplantable tumours. Biomed. Sci., 2, 111-120.
42. Shimonovitz, S., Hurwitz, A., Barak, V. et al. (1996) Cytokine-mediated regulation of type IV collagenase expression and production in human trophoblast cells. J Clin. Endocrinol. Metab., 81, 3091-3096
43. Sorenson, B., Montesano, R. and Harris, C.C. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22, 3551-3555.
44. Steinberg, P., Storkel, S., Oesch, F. et al. (1992) Carbohydrate metabolism in human renal clear cell carcinomas. Lab. Invest., 67, 506-511.
45. Tamakoshi, K., Kikkawa, F., Nawa, A. et al. (1994) Different pattern of zymography betwen human gynecologic normal and malignant tissue. Am. J. Obstet. Gynecol., 171, 478-484.
46. 14C-glucose. Anal. Biochem., 25, 486-499.
47. Tienary, J., Pertovaara, L., Saksela, O. et al. (1994) Increased expression of the matrix metalloproteinase 2 in differentiating Tera 2 human embryonal carcinoma cells. Int. J. Cancer, 15, 219-223.
48. Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Sci. USA, 76, 4350-4354.
49. Vassali, J.-D. and Belin, D. (1987) Amiloride selectively inhibits the urokmase-type plasminogen activator. FEBS Lett., 214, 187-191.
50. Weiss, D.J. and Gurpide, E. (1988) Non-genomic effects of estrogens and antiestrogens. J. Steroid Biochem., 31, 671-676
51. Zaoui, D., Le Fevre, B., Magdlenat, H. et al. (1984) A simple spectrophotometric assay of plasminogen activator: comparison with the fibrinolytic method. Clin. Chim. Acta, 141, 101-109.
52. Zhang, J.J., Jacob, T.J.C., Valverde, M.A. et al. (1994) Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J. Clin. Invest., 94, 1690-1697.